BRPI0409690A - associação terapêutica de um inibidor de cox-2 e um inibidor de aromatase - Google Patents

associação terapêutica de um inibidor de cox-2 e um inibidor de aromatase

Info

Publication number
BRPI0409690A
BRPI0409690A BRPI0409690-8A BRPI0409690A BRPI0409690A BR PI0409690 A BRPI0409690 A BR PI0409690A BR PI0409690 A BRPI0409690 A BR PI0409690A BR PI0409690 A BRPI0409690 A BR PI0409690A
Authority
BR
Brazil
Prior art keywords
inhibitor
cox
aromatase
therapeutic combination
aromatase inhibitor
Prior art date
Application number
BRPI0409690-8A
Other languages
English (en)
Inventor
Jaime L Masferrer
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0409690A publication Critical patent/BRPI0409690A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"ASSOCIAçãO TERAPêUTICA DE UM INIBIDOR DE COX-2 E UM INIBIDOR DE AROMATASE". A presente invenção proporciona composições e métodos para tratamento, prevenção ou inibição de uma neoplasia, uma patologia relacionada com neoplasias ou osteoporose num mamífero utilizando uma associação de um inibidor de COX-2 e um inibidor de aromatase.
BRPI0409690-8A 2003-04-23 2004-04-22 associação terapêutica de um inibidor de cox-2 e um inibidor de aromatase BRPI0409690A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/421,685 US20040053900A1 (en) 1998-12-23 2003-04-23 Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
PCT/US2004/012417 WO2004093868A1 (en) 2003-04-23 2004-04-22 Therapeutic combination of a cox-2 inhibitor and an aromatase inhibitor

Publications (1)

Publication Number Publication Date
BRPI0409690A true BRPI0409690A (pt) 2006-04-18

Family

ID=33309581

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409690-8A BRPI0409690A (pt) 2003-04-23 2004-04-22 associação terapêutica de um inibidor de cox-2 e um inibidor de aromatase

Country Status (7)

Country Link
US (1) US20040053900A1 (pt)
EP (1) EP1653940A1 (pt)
JP (1) JP2006524259A (pt)
BR (1) BRPI0409690A (pt)
CA (1) CA2522960A1 (pt)
MX (1) MXPA05011501A (pt)
WO (1) WO2004093868A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
WO2006096778A2 (en) * 2005-03-08 2006-09-14 Mitsui Norin Co., Ltd Polyphenol coxib combinations and methods
WO2007089735A2 (en) * 2006-02-01 2007-08-09 Merck & Co., Inc. Potassium channel inhibitors
SG178716A1 (en) * 2007-01-16 2012-03-29 Ipintl Llc Novel composition for treating metabolic syndrome
JP2010533205A (ja) 2007-07-12 2010-10-21 トラガラ ファーマシューティカルズ，インク． 癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物
EP2205075A4 (en) * 2007-09-24 2010-12-29 Tragara Pharmaceuticals Inc THERAPIES FOR THE TREATMENT OF CANCER BASED ON COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND OSTROGEN RECEPTOR ANTAGONISTS
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
WO2010014249A1 (en) * 2008-08-01 2010-02-04 Cell Therapeutics, Inc. Cancer therapy comprising estrogen inhibitors
WO2010107702A1 (en) * 2009-03-16 2010-09-23 Ipintl, Llc Treating alzheimer's disease and osteoporosis and reducing aging
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
CN102465144A (zh) * 2010-11-19 2012-05-23 中国科学院上海巴斯德研究所 柯萨奇病毒a16型病毒样颗粒疫苗
ES2694582T3 (es) * 2011-01-31 2018-12-21 Lucolas-M.D. Ltd. Combinaciones de inhibidores de aromatasa y antioxidantes
TWI646091B (zh) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE271385T1 (de) * 1996-10-15 2004-08-15 Searle Llc Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
PA8469401A1 (es) * 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
DE69917124T2 (de) * 1998-04-10 2005-05-12 Pfizer Products Inc., Groton Cyclobutyl-Aryloxysulfonylamin-Hydroxamsäurederivate
US6294558B1 (en) * 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6277878B1 (en) * 1998-09-07 2001-08-21 Pfizer Inc Substituted indole compounds as anti-inflammatory and analgesic agents
EP1004578B1 (en) * 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
WO2000038715A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
DE60003863T2 (de) * 1999-03-31 2004-04-22 Pfizer Products Inc., Groton Dioxocyclopentylhydroxamsäure
JP2004508334A (ja) * 2000-09-08 2004-03-18 フアルマシア・イタリア・エツセ・ピー・アー 化学予防剤としてのエクセメスタン
EP1377298B1 (en) * 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane for treating hormono-dependent disorders
PL370080A1 (en) * 2001-10-10 2005-05-16 Pharmacia Italia Spa Methods for preventing and treating bone loss with steroid compounds
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2522960A1 (en) 2004-11-04
EP1653940A1 (en) 2006-05-10
US20040053900A1 (en) 2004-03-18
JP2006524259A (ja) 2006-10-26
MXPA05011501A (es) 2005-12-15
WO2004093868A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
BR0011172A (pt) Derivados do 4,5-diaril-3(2h)-furanona como inibidores de cliclooxigenase-2
BR0207977A (pt) Métodos de combinação de inibição de crescimento tumoral com um antagonista de receptor de fator de crescimento endotelial
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
AU2016204344A1 (en) Improved methods and compositions for wound healing
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
TW200716141A (en) Compositions and methods for treatment for neoplasms
TW200640924A (en) VEGF-R2 inhibitors and methods
WO2007051065A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
SI1761520T1 (sl) Inhibitorji kinaze
ECSP077426A (es) USO DE UN INHIBIDOR DE mTOR EN EL TRATAMIENTO DE LEIOMIOMA UTERINO
MXPA05011501A (es) Combinacion terapeutica de un inhibidor de cox-2 y un inhibidor de aromatasa.
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
CO2022000266A2 (es) Inhibidores de enzimas
EA200900073A1 (ru) КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
BRPI0409473A (pt) combinação de um inibidor de cox-2 e um agente antineoplásico do tipo alquilante para o tratamento de neoplasia
MX2007012703A (es) Compuestos de piperazina o diaza-ciclicos sustituidos por 2-amino-carbonilo como moduladores del inhibidor de la proteina de apoptosis (iap).
SI1831209T1 (sl) Zaviralci fosfataz cdc25
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas
UA100296C2 (uk) Адипонектин для лікування захворювань легенів
PA8621401A1 (es) Tratamiento de la osteoporosis relacionada con la terapia de inhibidor de aromatasa
BRPI0407039A (pt) Uso de uma combinação de um inibidor de aromatase, uma progestina e um estrogênio, composição farmacêutica, e, método do tratamento de endometriose
BR0317491A (pt) Método de usar um inibidor de cox-2 e um inibidor de topoisomerase ii como uma terapia de combinação no tratamento de neoplasia
PT1292290E (pt) Composicoes farmaceuticas que compreendem derivados de acriloil-distamicina e inibidores de topoisomerase 1 e ii

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]